Company intelligence / Profile preview

Yunnan Hansu Biotechnology

Kunming City, Yunnan Province, Chinahansumi.com ↗

Ownership: Private
Development stage: Other

Overview

Yunnan Hansu Biotechnology is a subsidiary of HMI Group focused on the extraction and production of industrial hemp-derived cannabinoids including cannabidiol (CBD), cannabidivarine (CBDV), cannabigerol (CBG), and tetrahydrocannabivarin (THCV). The company operates a licensed extraction facility in Kunming, China, with government approval for industrial hemp processing. Its main products include high-purity cannabinoid isolates and full-spectrum hemp oils for use in pharmaceutical ingredients or health-related applications.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (cannabinoids)
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Yunnan Hansu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunnan Hansu Biotechnology.

Explore the full profile